- Educatie
- Bron: Campus Sanofi
- 13 dec 2024
The Hematology Podcast - Season 1
Welcome to The Hematology Podcast, your source for the latest insights into hematology and rare blood disorders. This podcast covers cutting-edge research, clinical advancements, and real-world cases tailored for healthcare professionals. Each episode offers expert perspectives on evolving therapies and best practices, helping you stay informed and improve patient outcomes. Whether you're focused on research or clinical practice, The Hematology Podcast is designed to keep you at the forefront of the field, transforming your approach to hematology.
Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies? With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami.
Expert guest
Ola Landgren
Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program
Sylvester Comprehensive Cancer Center, University of Miami
Detection of Minimal Residual Disease (MRD) is becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we’ve been able to improve the sensitivity of detecting minimal levels of MRD through innovations in molecular biology. But should MRD always be treated? Will it give a better outcome for the patient? And do the benefits outweigh the costs?
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Dr Fredrik Schjesvold, head of the Oslo Myeloma Center.
Expert guest
Dr Fredrik Schjesvold
Head of the Oslo Myeloma Center
Minimal residual disease (MRD) can today be evaluated in individual patient after treatment using various methods with high sensitivity. MRD indicates remaining malignant cells that could be a source of relapse of the disease. Could MRD also be used as an efficient endpoint in the design of new clinical studies? With help from Professor Ola Landgren, we will look into the crystal ball and discover what the future may hold for MRD.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Ola Landgren, Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program. Sylvester Comprehensive Cancer Center, University of Miami.
Expert guest
Ola Landgren
Professor of Medicine, Chief of Myeloma Program & Experimental Therapeutics Program
Sylvester Comprehensive Cancer Center, University of Miami
Detection of Minimal Residual Disease (MRD) is becoming more important in different fields of hematology including Multiple Myeloma. Over the past decades we’ve been able to improve the sensitivity of detecting minimal levels of MRD through innovations in molecular biology. But should MRD always be treated? Will it give a better outcome for the patient? And do the benefits outweigh the costs?
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Dr Fredrik Schjesvold, head of the Oslo Myeloma Center.
Expert guest
Dr Fredrik Schjesvold
Head of the Oslo Myeloma Center
One drop of blood, two sheets of glass, 40x objective. Hematological diagnostics demands a keen eye and sound reasoning. At the same time, artificial intelligence is entering the field in a big way. We ask: are the days of Giemsa coloring past us? What will machines be able to do for us, and is there a new role for humans in hematological diagnostics?
Host for the podcast is the Swedish hematologist Mats Merup. Special guests in this episode are Birgitta Sander, basic researcher and pathologist, senior physician and professor at Karolinska Institute and Morten Goodwin, researcher and professor at the University of Agder in the field of artificial Intelligence.
Expert guest
Birgitta Sander
Basic researcher and pathologist
Senior physician and professor at Karolinska Institute
Morten Goodwin
Researcher and professor at the University of Agder in the field of artificial Intelligence
We’re currently able to scan the entire human genome in a single day, and the application of genetic sequencing has the potential to improve diagnosis, prognosis and treatment. Ahead lies the opportunity to easily discover rare hematological diseases that might previously have gone unnoticed or would have been hard to diagnose. We look closer at genetic sequencing and discuss its applications.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Professor Janna Saarela. Jaana is the director of the Norwegian Centre for molecular medicine, and a researcher working to improve our understanding of the disease pathogenesis and mechanisms of human immune disorder.
Expert guest
Professor Janna Saarela
Director of the Norwegian Centre for molecular medicine, and a researcher working to improve our understanding of the disease pathogenesis and mechanisms of human immune disorder
One drop of blood, two sheets of glass, 40x objective. Hematological diagnostics demands a keen eye and sound reasoning. At the same time, artificial intelligence is entering the field in a big way. We ask: are the days of Giemsa coloring past us? What will machines be able to do for us, and is there a new role for humans in hematological diagnostics?
Host for the podcast is the Swedish hematologist Mats Merup. Special guests in this episode are Birgitta Sander, basic researcher and pathologist, senior physician and professor at Karolinska Institute and Morten Goodwin, researcher and professor at the University of Agder in the field of artificial Intelligence.
Expert guest
Birgitta Sander
Basic researcher and pathologist
Senior physician and professor at Karolinska Institute
Morten Goodwin
Researcher and professor at the University of Agder in the field of artificial Intelligence
We’re currently able to scan the entire human genome in a single day, and the application of genetic sequencing has the potential to improve diagnosis, prognosis and treatment. Ahead lies the opportunity to easily discover rare hematological diseases that might previously have gone unnoticed or would have been hard to diagnose. We look closer at genetic sequencing and discuss its applications.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Professor Janna Saarela. Jaana is the director of the Norwegian Centre for molecular medicine, and a researcher working to improve our understanding of the disease pathogenesis and mechanisms of human immune disorder.
Expert guest
Professor Janna Saarela
Director of the Norwegian Centre for molecular medicine, and a researcher working to improve our understanding of the disease pathogenesis and mechanisms of human immune disorder
aTTP is a hematological disease so rare that all professionals struggle to identify it. In this episode, we talk to a hematologist who has diagnosed and treated a patient with aTTP, and we discover what actions a hematologist takes, when facing a deadly acute disease which has six incidents per million in a year.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Henrik Frederiksen, Chief Physician, clinical associate professor, Phd, Department of Haematology X, Odense University Hospital and the Department of Clinical Research, University of Southern Denmark.
Expert guest
Henrik Frederiksen
Chief Physician, Clinical associate professor, Phd, Department of Haematology X, Odense University Hospital
Department of Clinical Research, University of Southern Denmark
aTTP is a hematological disease so rare that all professionals struggle to identify it. In this episode, we talk to a hematologist who has diagnosed and treated a patient with aTTP, and we discover what actions a hematologist takes, when facing a deadly acute disease which has six incidents per million in a year.
Host for the podcast is the Swedish hematologist Mats Merup. Special guest in this episode is Henrik Frederiksen, Chief Physician, clinical associate professor, Phd, Department of Haematology X, Odense University Hospital and the Department of Clinical Research, University of Southern Denmark.
Expert guest
Henrik Frederiksen
Chief Physician, Clinical associate professor, Phd, Department of Haematology X, Odense University Hospital
Department of Clinical Research, University of Southern Denmark
Get to know the host
In each episode, Dr. Mats Merup leads the interviews with the respective experts, providing a deep dive into the clinical, theoretical and practical aspects of the hematological field.
Associate professor Mats Merup, MD PhD (host)
Hematologist
Stockholm, Sweden
Mats Merup is an experienced clinical hematologist with an MD and PhD, specializing in malignant lymphomas and myeloproliferative disorders. He currently works in the clinical setting and has contributed to 50 published research publications as a clinical researcher.
Other channels to subscribe
The Hematology Podcast
Don’t miss the next episode, go to your favorite player and subscribe to the podcast
For additional insights and resources in hematology, refer to the following sites:
Educational programs for healthcare professionals
Educational programs for healthcare professionals
Neem contact op
MAT-BE-2401125 - 1.0 - 12/2024